Oncolytic virotherapy: the questions and the promise

References

• VisvaderLELindemanGJCancer stem cells: current status and evolving complexitiesCell Stem Cell20121071772822704512
   PubMed Web of Science ®Google Scholar
• ZeyaullahMPatroMAhmadIOncolytic viruses in the treatment of cancer: a review of current strategiesPathol Oncol Res20121877178122714538
   PubMed Web of Science ®Google Scholar
• SenzerNNKaufmanHLAmatrudaTPhase II clinical trial of a granulocyte-macrophage Colony- stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanomaJ Clin Oncol2009275763577119884534
   PubMed Web of Science ®Google Scholar
• ParkBHHwangTLiuTCUse of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trialLancet Oncol2008953354218495536
   PubMed Web of Science ®Google Scholar
• HarringtonKJHingoraniMTanayMAPhase I/II study of oncolytic HSV GM-CSF in combination with radiotherapy and cisplatin in untreated stage III/IV squamous cell cancer of the head and neckClin Cancer Res2010164005401520670951
   PubMed Web of Science ®Google Scholar
• BartonKNStrickerHBrownSLPhase I study of noninvasive imaging of adenovirus-mediated gene expression in the human prostateMol Ther2008161761176918714306
   PubMed Web of Science ®Google Scholar
• KishimotoHUrataYTanakaNFujiwaraTHoffmanRMSelective metastatic tumor labeling with green fluorescent protein and killing by systemic administration of telomerase-dependent adenovirusesMol Cancer Ther200983001300819887549
   PubMed Web of Science ®Google Scholar
• KishimotoHZhaoMHayashiKIn vivo internal tumor illumination by telomerase-dependent adenoviral GFP for precise surgical navigationProc Natl Acad Sci U S A2009106145141451719706537
   PubMed Web of Science ®Google Scholar
• GuseKDiasJDBauerschmitzGJLuciferase imaging for evaluation of oncolytic adenovirus replication in vivoGene Ther20071490291117377596
   PubMed Web of Science ®Google Scholar
• HuynSTBurtonJBSatoMCareyMGambhirSSWuLA potent, imaging adenoviral vector driven by the cancer-selective mucin-1 promoter that targets breast cancer metastasisClin Cancer Res2009153126313419366829
   PubMed Web of Science ®Google Scholar
• NemunaitisITongAWNemunaitisMA phase I study of telomerase-specific replication competent oncolytic adenovirus (telomelysin) for various solid tumorsMol Ther20101842943419935775
   PubMed Web of Science ®Google Scholar
• ShashkovaEVMaySMDoroninKBarryMAExpanded anticancer therapeutic window of hexon-modified oncolytic adenovirusMol Ther2009172121213019755961
   PubMed Web of Science ®Google Scholar
• MuikAKneiskeIWerbizkiMPseudotyping vesicular stomatitis virus with lymphocytic choriomeningitis virus glycoproteins enhances infectivity for glioma cells and minimizes neurotropismJ Virol2011855679568421450833
   PubMed Web of Science ®Google Scholar
• PanWBodempudiVEsfandyariTFarassatiFUtilizing ras signaling pathway to direct selective replication of herpes simplex virus-1PLoS One20094e651419652721
   PubMed Web of Science ®Google Scholar
• ColungaAGLaingMAurelianLThe HSV-2 mutant DeltaPK induces melanoma oncolysis through nonredundant death programs and associated with autophagy and pyroptosis proteinsGene Ther20101731532719798049
   PubMed Web of Science ®Google Scholar
• CawoodRChenHHCarrollFBazan-PeregrinoMvan RooijenNSeymourLWUse of tissue-specific microRNA to control pathology of wild-type adenovirus without attenuation of its ability to kill cancer cellsPLoS Pathog20095e100044019461878
   PubMed Web of Science ®Google Scholar
• SugioKSakuraiFKatayamaKEnhanced safety profiles of the telomerase-specific replication-competent adenovirus by incorporation of normal cell-specific microRNA-targeted sequencesClin Cancer Res2011172807281821346145
   PubMed Web of Science ®Google Scholar
• GuedanSRojasJJGrosAMercadeECascalloMAlemanyRHyaluronidase expression by an oncolytic adenovirus enhances its intratumoral spread and suppresses tumor growthMol Ther2010181275128320442708
   PubMed Web of Science ®Google Scholar
• SchogginsJWWilsonSJPanisMA diverse range of gene products are effectors of the type I interferon antiviral responseNature201147248148521478870
   PubMed Web of Science ®Google Scholar
• Le BoeufFDialloJSMcCartJASynergistic interaction between oncolytic viruses augments tumor killingMol Ther20101888889520234341
   PubMed Web of Science ®Google Scholar
• NguyênTLAbdelbaryHArguelloMChemical targeting of the innate antiviral response by histone deacetylase inhibitors renders refractory cancers sensitive to viral oncolysisProc Natl Acad Sci U S A2008105149811498618815361
   PubMed Web of Science ®Google Scholar
• AlainTLunXMartineuaYVesicular stomatitis virus oncolysis is potentiated by impairing mTORC1-dependent type I IFN productionProc Natl Acad Sci U S A20101071576158120080710
   PubMed Web of Science ®Google Scholar
• QiaoJWangHKottkeTCyclophospharnide facilitates antitumor efficacy against subcutaneous tumors following intravenous delivery of reovirusClin Cancer Res20081425926918172278
   PubMed Web of Science ®Google Scholar
• HaismaHJBoesjesMBeerensAMScavenger receptor A: a new route for adenovirus 5Mol Pharm2009636637419227971
   PubMed Web of Science ®Google Scholar
• DoroninKShashkovaEVMaySMHofherrSEBarryMAChemical modification with high molecular weight polyethylene glycol reduces transduction of hepatocytes and increases efficacy of intravenously delivered oncolytic adenovirusHum Gene Ther20092097598819469693
   PubMed Web of Science ®Google Scholar
• GreenNKHerbertCWHaleSJExtended plasma circulation time and decreased toxicity of polymer-coated adenovirusGene Ther2004111256126315215884
   PubMed Web of Science ®Google Scholar
• IkedaKWakimotoHIchikawaTComplement depletion facilitates the infection of multiple brain tumors by an intravascular, replication-conditional herpes simplex virus mutantJ Virol2000744765477510775615
   PubMed Web of Science ®Google Scholar
• DwyerRMKhanSBarryFPO’BrienTKerinMJAdvances in mesenchymal stem cell-mediated gene therapy for cancerStem Cell Res Ther201012520699014
   PubMed Web of Science ®Google Scholar
• IlettEJBarcenaMErrington-MaisFInternalization of oncolytic reovirus by human dendritic cell carriers protects the virus from neutralizationClin Cancer Res2011172767277621389099
   PubMed Web of Science ®Google Scholar
• IankovIDBlechaczBLiuCInfected cell carriers: a new strategy for systemic delivery of oncolytic measles viruses in cancer virotherapyMol Ther20071511412217164782
   PubMed Web of Science ®Google Scholar
• ChenHHCawoodREl-SherbiniYActive adenoviral vascular penetration by targeted formation of heterocellular endothelial-epithelial syncytiaMol Ther201119677520877345
   PubMed Web of Science ®Google Scholar
• OngHTTrejoTRPhamLDObergALRussellSJPengKWIntravascularly administered RGD-displaying measles viruses bind to and infect neovessel endothelial cells in vivoMol Ther2009171012102119277014
   PubMed Web of Science ®Google Scholar
• TsengJCGranotTDiGiacomoVLevinBMerueloDEnhanced specific delivery and targeting of oncolytic Sindbis viral vectors by modulating vascular leakiness in tumorCancer Gene Ther20101724425519798121
   PubMed Web of Science ®Google Scholar
• KottkeTHallGPulidoJAntiangiogenic cancer therapy combined with oncolytic virotherapy leads to regression of established tumors in miceClin Invest201012015511560
   Google Scholar
• MelcherAParatoKRooneyCMBellJCThunder and lightning: immunotherapy and oncolytic viruses collideMol Ther201161008101621505424
   PubMed Web of Science ®Google Scholar
• DiazRMGalivoFKottkeTOncolytic immunovirotherapy for melanoma using vesicular stomatitis virusCancer Res2007672840284817363607
   PubMed Web of Science ®Google Scholar
• TodoTActive immunotherapy: oncolytic virus therapy using HSV-1Adv Exp Med2012746178186
   Web of Science ®Google Scholar
• MarcatoPDeanCAGiacomantonioCALeePWOncolytic reovirus effectively targets breast cancer stem cellsMol Ther20091797297919293772
   PubMed Web of Science ®Google Scholar
• LunXChanIZhouHEfficacy and safety/toxicity study of recombinant vaccinia virus JX-594 in two immunocompetent animal models of gliomaMol Ther2010181927193620808290
   PubMed Web of Science ®Google Scholar
• ContagCHSikorskiRNegrínRSDefinition of an enhanced immune cell therapy in mice that can target stem-like lymphoma cellsCancer Res2010709837984520935221
   PubMed Web of Science ®Google Scholar
• NandiSUlasovIVTylerMALow-dose radiation enhances survivin-mediated virotherapy against malignant glioma stem cellsCancer Res2008685778578418632631
   PubMed Web of Science ®Google Scholar
• MahllerYYWilliamsIPBairdWHNeuroblastoma cell lines contain pluripotent tumor initiating cells that are susceptible to a targeted oncolytic virusPLoS One20094e423519156211
   PubMed Web of Science ®Google Scholar
• ZhuGSuWJinGGlioma stem cells targeted by oncolytic virus carrying endostatin-angiostatin fusion gene and the expression of its exogenous gene in vitroBrain Res20111390596921443868
   PubMed Web of Science ®Google Scholar
• DmitrievaNYuLViapianoMChondroitinase ABC I- mediated enhancement of oncolytic virus spread and antitumor efficacyClin Cancer Res2011171362137221177410
   PubMed Web of Science ®Google Scholar
• InoueDSuzukiTMitsuishiYAccumulation of p62/SQSTM1 is associated with poor prognosis in patients with lung adenocarcinomaCancer Sci201210376076622320446
   PubMed Web of Science ®Google Scholar
• ChenNBelloneCJSchriewerJPoxvirus interleukin-4 expression overcomes inherent resistance and vaccine-induced immunity: pathogenesis, prophylaxis, and antiviral therapyVirology201140932833721071055
   PubMed Web of Science ®Google Scholar
• ShortHCurielDTOncolytic adenoviruses targeted to cancer stem cellsMol Cancer Ther200982096210219671759
   PubMed Web of Science ®Google Scholar
• LiXMaoOWangDZiieirieIWXiaHA fiber chimeric CRAd vector Ad5/11-D24 double-armed with TRAIL and arresten for enhanced glioblastoma therapyHum Gene Ther20122358959622136065
   PubMed Web of Science ®Google Scholar
• WatanabeTHiokiMFujiwaraTHistone deacetylase inhibitor FR901228 enhances the antitumor effect of telomerase-specific replication-selective adenoviral agent OBP-301 in human lung cancer cellsExp Cell Res200631225626516356494
   PubMed Web of Science ®Google Scholar
• LiuLWuWZhuGTherapeutic efficacy of an hTERT promoter-driven oncolytic adenovirus that expresses apoptin in gastric carcinomaInt J Mol Med20123074775422842823
   PubMed Web of Science ®Google Scholar
• TakiMKagawaSNishizakiMEnhanced oncolysis by a tropism-modified telomerase-specific replication-selective adenoviral agent (‘Telomelysin-RGD’)Oncogene2005243130314015735729
   PubMed Web of Science ®Google Scholar
• HittMMGrahamFLAdenovirus E1A under the control of heterologous promoters: wide variation in E1A expression levels has little effect on virus replicationVirology19901796676782146801
   PubMed Web of Science ®Google Scholar
• SugioKSakuraiFKatavamaKEnhanced safety profiles of the telomerase-specific replication-competent adenovirus by incorporation of normal cell-specific microRNA-targeted sequencesClin Cancer Res2011172807281821346145
   PubMed Web of Science ®Google Scholar
• YamasakiYTazawaHHashimotoYA novel apoptotic mechanism of genetically engineered adenovirus-mediated tumour-specific p53 overexpression through E1A-dependent p21 and MDM2 suppressionEur J Cancer2012482282229122244827
   PubMed Web of Science ®Google Scholar
• PesonenSHelinHNokisalmiPOncolytic adenovirus treatment of a patient with refractory neuroblastomaActa Oncol20104911711919735000
   PubMed Web of Science ®Google Scholar
• García-CastroJAlemanyRCascalloMTreatment of metastatic neuroblastoma with systemic oncolytic virotherapy delivered by autologous mesenchymal stem cells: an exploratory studyCancer Gene Ther20101747648320168350
   PubMed Web of Science ®Google Scholar
• KoskiARakiMNokisalmiPVerapamil results in increased blood levels of oncolytic adenovirus in treatment of patients with advanced cancerMol Ther20122022122922044933
   PubMed Web of Science ®Google Scholar
• McCartJAWardJMLeeJSystemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genesCancer Res200161875l8757
   Web of Science ®Google Scholar
• KirnDHWangYLe BoeufFBellIThorneSHTargeting of interferon-beta to produce a specific, multi-mechanistic oncolytic vaccinia virusPLoS Med20074e35318162040
   PubMed Web of Science ®Google Scholar
• GuseKCerulloVHemminkiAOncolytic vaccinia virus for the treatment of cancerExpert Opin Biol Ther20111159560821338330
   PubMed Web of Science ®Google Scholar
• DonatUWeibelSHessMPreferential colonization of metastases by oncolytic vaccinia virus strain GLV-1h68 in a human PC-3 prostate cancer model in nude micePLoS One20127e4594223049897
   PubMed Web of Science ®Google Scholar
• MansfieldDPencavelTKyulaJNOncolytic vaccinia virus and radiotherapy in head and neck cancerOral Oncol20134910811822925693
   PubMed Web of Science ®Google Scholar
• BreitbachCJBurkeJJonkerDIntravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humansNature20114779910221886163
   PubMed Web of Science ®Google Scholar
• TysomeJRLiXWangSA novel therapeutic regimen to eradicate established solid tumor with an effective induction of tumor-specific immunityClin Cancer Res2012186679668923091113
   PubMed Web of Science ®Google Scholar
• OrvedahlAAlexanderDTallóczyZHSV-1 ICP345 confers neurovirulence by targeting the Beclin 1 autophagy proteinCell Host Microbe20071233518005679
   PubMed Web of Science ®Google Scholar
• KanaiRZaupaCSgubinDEffect of γ34.5 deletions on oncolytic herpes simplex virus activity in brain tumorsJ Virol2012864420443122345479
   PubMed Web of Science ®Google Scholar
• HunterWDMartuzaRLFeigenbaumFAttenuated, replication-competent herpes simplex virus type 1 mutant G207: safety evaluation of intracerebral injection in nonhuman primatesJ Virol1999736319632610400723
   PubMed Web of Science ®Google Scholar
• RamplingRCruickshankGPapanastassiouVToxicity evaluation of replication-competent herpes simplex virus ICP 34.5 null mutant 1716 in patients with recurrent malignant gliomaGene Ther2000785986610845724
   PubMed Web of Science ®Google Scholar
• UchidaHMarzulliMNakanoKEffective treatment of an orthotopic xenograft model of human glioblastoma using an EGFR-retargeted oncolytic herpes simplex virusMol Ther20132156156923070115
   PubMed Web of Science ®Google Scholar
• KambaraHOkanoHChioccaEASaekiYAn oncolytic HSV-1 mutant expressing ICP345 under control of a nestin promoter increases survival of animals even when symptomatic from a brain tumorCancer Res2005652832283915805284
   PubMed Web of Science ®Google Scholar
• MahllerYYVaikunthSSRipbergerMCTissue inhibitor of metalloproteinase-3 via oncolytic herpesvirus inhibits tumor growth and vascular progenitorsCancer Res2008681170117918281493
   PubMed Web of Science ®Google Scholar
• Alvarez-BreckenridgeCAYuIPriceRNK cells impede glioblastoma virotherapy through NKp30 and NKp46 natural cytotoxicity receptorsNat Med2012181827183423178246
   PubMed Web of Science ®Google Scholar
• FuXRiveraATaoLZhangXIncorporation of the B18R gene of vaccinia virus into an oncolytic herpes simplex virus improves antitumor activityMol Ther2012201871188122692498
   PubMed Web of Science ®Google Scholar
• ConnerIBraidwoodLExpression of inhibitor of growth 4 by HSV1716 improves oncolytic potency and enhances efficacyCancer Gene Ther20121949950722595793
   PubMed Web of Science ®Google Scholar
• KanaiRRabkinSDYinSOncolytic virus-mediated manipulation of DNA damage responses: synergy with chemotherapy in killing glioblastoma stem cellsJ Natl Cancer Inst2012104425522173583
   PubMedGoogle Scholar
• TouchefeuYVassauxGHarringtonKIOncolytic viruses in radiation oncologyRadiother Oncol20119926227021704402
   PubMed Web of Science ®Google Scholar
• NguyenTLTumilasciVFSinghroyDArguelloMHiscottIThe emergence of combinatorial strategies in the development of RNA oncolytic virus therapiesCell Microbiol20091188989719388908
   PubMed Web of Science ®Google Scholar